Floatz logo

nn3201

Neuroendocrine Tumors

Novelty Nobility, Inc.antibody_drug_conjugatePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

nn3201 is also rated in:

gastrointestinal stromal tumorDormant
CC
Indicative ·
43 / 100
View asset →
adenoid cystic carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
chromophobe renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →